Research On Qige Powder Increases Esophageal EC9706 Cells To Cisplatin Sensitivity Mechanism

ObjectiveThrough research Qige powder-containing serum combined cisplatin in human esophageal cancer cells EC9706 proliferation, apoptosis, cycle, and the related genes miR-21, PDCD4, PTEN protein expression and regulation function, preliminary discussion and Qige powder-containing serum combined increase human esophageal cancer EC9706 cells to cisplatin sensitivity mechanism and provide theoretical basis for clinical application.MethodsPreparation and Qige powder drug-containing serum, with different concentrations of serum medicated with cisplatin combination of concentration in 48 h of EC9706 cells, with a determined by MTT method to screen out the most effective drug-containing serum concentrations (5% medicated serum). Respectively 5% with 5% medicated serum and cisplatin, compared with cisplatin,5% medicated serum,5% control effect on serum EC9706 cells, flow cytometry is used to test their effects on EC9706 cell apoptosis, cycle; Application of PCR detection related genes miR-21, PDCD4, PTEN expression; Using Western blot method-testing related PDCD4 and PTEN protein expression level.Results1.10%,5%,2.5% medicated serum and cisplatin plus applications have synergy, of which 5% medicated serum with cisplatin, synergistic effect and the most significant.2. EC9706 cells by different concentration of drug effect after 48 h, compared with control group, in addition to the 5% medicated serum groups (P> 0.05), cisplatin, low concentration, high concentration group, combined high concentrations of cisplatin, medicated serum medicated serum combined cisplatin group, low concentration cell apoptosis rate are higher, with statistical significance (P< 0.05); Compared with single 5% medicated serum group, combined cisplatin group of low concentration and high concentration of cisplatin group of cell apoptosis rate has increased (P < 0.05), respectively in comparison with concentration of cisplatin group, medicated serum joint low concentration cisplatin group of apoptosis rate increased (P< 0.05), joint high concentration showed no difference (P> 0.05).3. EC9706 cells by different concentration of drug effect after 48 h, compared with control serum, add S phase cells after cisplatin were increased (P< 0.05), of which0.5?g/ml cisplatin group increased significantly. Medicated serum joint high concentrations of cisplatin than single use cisplatin S phase proportion with the concentration increased, G2 lower (P< 0.05), there is statistical significance; Medicated serum concentration of combined with low concentration of cisplatin and used alone cisplatin than no statistical difference (P> 0.05).4. Compared with 5% control serum group, the rest of the group miR-21 relative quantitative have increased (P< 0.05); Whether high concentrations of cisplatin or low concentration cisplatin group, a joint after medicated serum miR-21 quantitative are relatively lower than alone (P< 0.05). Table 5 results shows:compared with 5% against serogroup, except 5%medicated serum PDCD4 expression decreased, the rest of the group to express quantity increased (P< 0.05); Serum groups than the low concentration of cisplatin plus alone PDCD4 expression quantity increased (P< 0.05), high concentration of cisplatin plus serogroup PDCD4 expression than their single use declined (P< 0.05); Compared with 5% against serogroup,0.5?g/ml cisplatin group and 5% medicated serum PTEN expression decreased, the rest of the group were higher (P< 0.05), cisplatin plus serum in the two groups were is higher than the number of PTEN expression cisplatin alone two groups (P< 0.05).5. Compared with the control group, each group PDCD4 protein expression quantity increased (P< 0.05; High concentrations of cisplatin plus medicated serum than use seibel platinum group PDCD4 protein expression quantity increased (P< 0.05), low concentration of cisplatin does not change significantly in the two groups (P st13 0.05); Two cisplatin plus medicated serum concentration when the expression of PTEN was higher than that of single use cisplatin (P< 0.05).Conclusion1. Qige powder scattered combined cisplatin application to human esophageal cancer cell lines EC9706 inhibition have synergy.2. Qige powder can improve the cisplatin induced human esophageal cancer cell lines EC9706 the role of apoptosis and S phase retardation rate.3. Qige powder spread combined cisplatin can cut miR-21 expression, raise target PDCD4 gene and the expression of PTEN and its protein. Rev Qige powder powder can increase the EC9706 of cisplatin sensitivity, and the mechanism may be mediated by miR-21 and its regulation and control of its downstream target genes of PDCD4 and PTEN in finish.